We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Investigational Drug Treatments for Triple-Negative Breast Cancer.
- Authors
Damaskos, Christos; Garmpis, Nikolaos; Garmpi, Anna; Nikolettos, Konstantinos; Sarantis, Panagiotis; Georgakopoulou, Vasiliki E.; Nonni, Afroditi; Schizas, Dimitrios; Antoniou, Efstathios A.; Karamouzis, Michalis V.; Nikolettos, Nikos; Kontzoglou, Konstantinos; Patsouras, Alexandros; Voutyritsa, Errika; Syllaios, Athanasios; Koustas, Evangelos; Trakas, Nikolaos; Dimitroulis, Dimitrios
- Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone therapy is largely ineffective for treatment purposes. Nevertheless, TNBC often responds very well to chemotherapy, which constitutes the most often recommended treatment. New beneficial targeted therapies are important to be investigated in order to achieve enhanced outcomes in patients with TNBC. This review will focus on recent therapeutic innovations for TNBC, focusing on various inhibitors such as phosphoinositide 3-kinase (PI3K) pathway inhibitors, poly-ADP-ribosyl polymerase (PARP) inhibitors, aurora kinase inhibitors, histone deacetylase inhibitors (HDACIs), and immune checkpoint inhibitors.
- Subjects
TRIPLE-negative breast cancer; INVESTIGATIONAL drugs; BREAST cancer; PHOSPHATIDYLINOSITOL 3-kinases; AURORA kinases
- Publication
Journal of Personalized Medicine, 2021, Vol 11, Issue 7, p652
- ISSN
2075-4426
- Publication type
Article
- DOI
10.3390/jpm11070652